Top 30 BIG Pharma
The phrase Big Pharma is normally used when referencing companies with revenues that exceed $3 billion, and/or R&D (Research & Development) expenditure which exceeds $500 million.
Big Bucks, Big Pharma
Marketing Disease and Pushing Drugs
is Now Available on DVD!
Learn more about Big Bucks, Big Pharma:
Summary
Logistical Information
Biographical Summary
Reviews and Comments
Screenings and Festivals
Articles
The following represents the Top 30 Pharmaceutical and Biotech companies ranked by healthcare revenue and R&D (Research & Development). Select companies may have additional chemicals revenue that is not included in this list.
Healthcare Revenue Rankings
| 2004 Rank | Company | Country | Healthcare Revenue (USD millions) | Healthcare R&D (USD millions) | Net Income/ (Loss) (USD millions) | Employees |
| 1 | Pfizer | USA | 52,516 | 7,684 | 11,361 | 115,000 |
| 2 | Johnson & Johnson | USA | 47,348 | 5,203 | 8,509 | 109,900 |
| 3 | GlaxoSmithKline | UK | 37,318 | 5,204 | 7,886 | 100,619 |
| 4 | Sanofi-Aventis | France | 31,615 | 4,927 | 6,526 | 96,439 |
| 5 | Novartis | Switzerland | 28,247 | 4,207 | 5,767 | 81,392 |
| 6 | Hoffmann-La Roche | Switzerland | 25,163 | 4,098 | 5,344 | 64,703 |
| 7 | Merck & Co. | USA | 22,939 | 4,010 | 5,813 | 62,600 |
| 8 | AstraZeneca | UK-Sweden | 21,427 | 3,803 | 3,813 | 64,200 |
| 9 | Abbott Laboratories | USA | 19,680 | 1,697 | 3,236 | 50,600 |
| 10 | Bristol-Myers Squibb | USA | 19,380 | 2,500 | 2,388 | 43,000 |
| 11 | Wyeth | USA | 17,358 | 2,461 | 1,234 | 51,401 |
| 12 | Eli Lilly and Company | USA | 13,858 | 2,591 | 1,810 | 44,500 |
| 13 | Bayer | Germany | 10,554 | 1,299 | 750 | 113,060 |
| 14 | Amgen | USA | 10,550 | 2,028 | 2,363 | 14,400 |
| 15 | Boehringer Ingelheim | Germany | 10,146 | 1,532 | 1,104 | 35,529 |
| 16 | Baxter International | USA | 9,509 | 517 | 388 | 48,000 |
| 17 | Takeda Pharmaceutical Co. | Japan | 9,330 | 1,285 | 2,636 | 14,510 |
| 18 | Schering-Plough | USA | 8,272 | 1,607 | -981 | 30,500 |
| 19 | Astellas Pharma | Japan | 7,904 | 1,213 | 566 | 15,500 |
| 20 | Procter & Gamble | USA | 7,786 | n/a | 7,257 | 110,000 |
| 21 | Schering | Germany | 5,103 | 1,143 | 622 | 26,131 |
| 22 | Merck KgaA | Germany | 5,018 | 611 | 836 | 28,877 |
| 23 | Eisai Co. | Japan | 4,857 | 744 | 527 | 8,295 |
| 24 | Novo Nordisk | Denmark | 4,847 | 727 | 837 | 20,285 |
| 25 | Teva Pharmaceutical Industries | Israel | 4,799 | 338 | 332 | 13,813 |
| 26 | Genentech | USA | 4,621 | 948 | 785 | 7,646 |
| 27 | Sankyo Co. | Japan | 4,329 | 822 | 459 | 11,444 |
| 28 | Akzo Nobel | The Netherlands | 4,037 | 644 | 1,065 | 61,400 |
| 29 | Alcon | Switzerland | 3,914 | 390 | 872 | 12,200 |
| 30 | Forest Laboratories | USA | 3,160 | 294 | 839 | 5,136 |
| 2005 Rank | Company | Pharma R&D Spend ($ B) | % of Sales |
| 1 | Pfizer | $7.4 | 16.7% |
| 2 | Johnson & Johnson | $6.3 | 28.3% |
| 3 | GlaxoSmithKline | $5.7 | 16.8% |
| 4 | AstraZeneca | $5.4 | 22.5% |
| 5 | Sanofi-Aventis | $4.8 | 14.9% |
| 6 | Novartis | $4.5 | 18.0% |
| 7 | Roche (includes Chugai) | $4.2 | 26.8% |
| 8 | Merck | $3.8 | 17.3% |
| 9 | Eli Lilly | $3.0 | 20.4% |
| 10 | Amgen | $2.3 | 19.2% |
| 11 | Schering-Plough | $1.9 | 25.0% |
| 12 | Abbott Labs | $1.8 | 12.9% |
| 13 | Takeda | $1.3 | 15.3% |
| 14 | Wyeth | $1.3 | 8.5% |
| 15 | Genentech | $1.3 | 23.6% |
| 16 | Astellas | $1.3 | 16.3% |
| 17 | Daiichi-Sankyo | $1.3 | 17.8% |
| 18 | Schering AG | $1.2 | 19.0% |
| 19 | Boehringer Ingelheim | $1.1 | 10.2% |
| 20 | Bayer | $1.1 | 14.5% |
| 21 | Novo Nordisk | $0.8 | 14.8% |
| 22 | Eisai | $0.7 | 14.6% |
| 23 | Merck KGaA | $0.7 | 15.2% |
| 24 | UCB (Belgium) | $0.6 | 25% |
| 25 | Serono (Switzerland) | $0.6 | 25.6% |
| 26 | Baxter International | $0.5 | 16.7% |
| 27 | Akzo Nobel | $0.5 | 17.2% |
| 28 | Genzyme (U.S.) | $0.5 | 20.8% |
| 29 | Altana (Germany) | $0.5 | 17.9% |
| 30 | Mitsubishi | $0.5 | 26.3% |
